San Francisco and San Diego may have a friendly rivalry for the top area of California for biotechs, but when you add them together, the combination is a force to be reckoned with. Read More
The torrid pace predicted for dealmaking going forward, as identified in the Reed Smith survey described in this issue, was reaffirmed in the fifth annual BDO Biotech Briefing, which found that M&A activity remains strong despite a tough third quarter for biotech stocks and IPOs. The briefing found that almost a quarter (23.6 percent) of companies included on the Nasdaq Biotechnology Index (NBI) have been involved in M&A transactions so far in 2015. Read More
